Immunotherapy for head and neck cancer: the future of treatment?

Expert Opinion on Biological Therapy

Volumn 17, Issue 6, 2017, Pages 701-708

  Xie, Xiujie ^a   O’Neill, Wendi ^a   Pan, Quintin ^a,b  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

and immunotherapy; Head and neck cancer; immune escape; immunosuppression

Indexed keywords

CANCER VACCINE; CHECKPOINT KINASE INHIBITOR; CYCLOPHOSPHAMIDE; DURVALUMAB; INDOMETACIN; INTERLEUKIN 2; IPILIMUMAB; MONOCLONAL ANTIBODY; NIVOLUMAB; PEMBROLIZUMAB; TICILIMUMAB; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

CANCER IMMUNOTHERAPY; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNE EVASION; IMMUNOMODULATION; PERSONALIZED MEDICINE; REVIEW; TUMOR IMMUNITY; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; T LYMPHOCYTE;

ANTIBODIES, MONOCLONAL; CANCER VACCINES; CARCINOMA, SQUAMOUS CELL; CTLA-4 ANTIGEN; CYTOKINES; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOTHERAPY; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES;

EID: 85019102759     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1080/14712598.2017.1315100     Document Type: Review

References (80)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008. Int J Cancer. 2010;127:2893–2917.
2. Siegel R, Miller K, Jemal A., Cancer statistics. CA Cancer J Clin. 2015;65:5–29.
3. Siegel R, Naishadham D, Jemal A., Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.
4. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.
5. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immuoediting:from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991–998.
6. Fakona S, Diamandis EP, Blasutig IM. Cancer immunotherapy:the beginning of the end of cancer? BMC Med. 2016;14:73–90.
7. Anaëlle D, Stéphanie D, Pascale H, et al. Immune suppression in head and neck cancers:a review. Clin Dev Immunol. 2010;2010:701657–701671.
8. Kuss I, Hathaway B, Ferris RL, et al. Imbalance in absolute counts of T lymphocyte subsets in patients with head and neck cancer and its relation to disease. Adv Otorhinolaryngol. 2005;62:161–172.
9. Schaefer C, Kim GG, Albers A, et al. Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer. 2005;92:913–920.
10. Strauss L, Bergmann C, Szczepanski M, et al. Aunique subset of CD4+CD25+ high Fox3+ T cells secreting interleukin-10 and transforming growth factor-beta 1 mediates suppression in the tumor microenvironment. Clin Cancer Res. 2007;13:4345–4354.
11. Anne KS, Ralph P, Barbara W. Permanent up-regulation of regulatory T-lymphocytes in patients with head and neck cancer. Int J Mol Med. 2010;26:67–75.
12. Li C, Shintani S, Terakado N, et al. Infiltration of tumor-associated macrophages in human oral squamous cell carcinoma. Oncol Rep. 2002;9:1219–1223.
13. Dasgupta S, Bhattacharya-Chatterjee M, O’Malley BW, et al. Inhibition of NK cell activity through TGF-beta 1 by down-regulation of NKG2D in a murine model of head and neck cancer. J Immunol. 2005;175:5541–5550.
14. Almand B, Resser JR, Lindman B, et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res. 2000;6:1755–1766
15. Tong CL, Kao J, Sikora AG. Recognizing and reversing the immunosuppressive tumor microenvironment of head and neck cancer. Immunol Res. 2012;54:266–274.• This article outlines immunosuppressive mechanisms in the HNSCC tumor microenvironment and potential approaches to enhance the antitumor immune response.
16. Ferris RL. Immunology and immunotherapy of head and neck cancer. J Clin Oncol. 2015;33:28–40.
17. Whiteside TL, Stanson J, Shurin MR, et al. Antigen-processing machinery in human dendritic cells:up-regulation by maturation and down-regulation by tumor cells. J Immunol. 2004;173:1526–1534.
18. Ferris RL, Whiteside TL, Ferrone S. Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clin Cancer Res. 2006;12:3890–3895.
19. Meissner M, Reichert TE, Kunkel M, et al. Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma:association with clinical outcome. Clin Cancer Res. 2005;11:2552–2560.
20. Bandoh N, Ogino T, Katayama A, et al. HLA class I antigen and transporter associated with antigen processing downregulation in metastatic lesions of head and neck squamous cell carcinoma as a marker of poor prognosis. Oncol Rep. 2010;23:933–939.
21. Lopez-Albaitero A, Nayak JV, Ogino T, et al. Role of antigen-processing machinery in the vitro resistance of squamous cell carcinoma of head and neck cells to recognition by CTL. J Immunol. 2006;176:3402–3409.
22. Badoual C, Hans S, Merillon N, et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res. 2013;73(1):128–138.
23. Lyford-Pike S, Peng S, Young GD, et al. Evidence for a role of the PD-1:PD-L1pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res. 2013;73(6):1733–1741.• This article showed the association between HPV infection and the PD-1/PD-L1 pathway to provide a rationale for treating HPV-associated HNSCC patients with PD1/PD-L1 inhibitors.
24. Mroz EA, Tward AD, Hammon RJ, et al. Intra-tumor genetic heterogeneity and mortality in head and neck cancer:analysis of data from the Cancer Genome Atlas. Plos Med. 2015;12:e1001786.
25. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nat Immunol. 2002;3:999–1005.
26. Antoniou AN, Powis SJ, Elliott T. Assembly and export of MHC class I peptide ligands. Curr Opin Immunol. 2003;15:75–81.
27. Ferris RL, Hunt JL, Ferrone S. Human leukocyte antigen (HLA) class I defects I head and neck cancer:molecular mechanisms and clinical significance. Immunol Res. 2005;33:113–133.
28. Mizukami Y, Kono K, Maruyama T, et al. Downregulation of HLA class I molecules in the tumor is associated with a poor prognosis in patients with oesophageal squamous cell carcinoma. Br J Cancer. 2008;99:1462–1467.
29. Ogino T, Shigyo H, Ishii H, et al. HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. Cancer Res. 2006;66:9281–9289.• This article provides evidence for the clinical significance of HLA class I antigen and the clinical course of the disease.
30. Grandis JR, Falkner DM, Melhem MF, et al. Human leukocyte antigen class I allelic and haplotype loss in squamous cell carcinoma of the head and neck:clinical and immunogenetic consequences. Clin Cancer Res. 2000;6:2794–2802.
31. Allen CT, Judd NP, Bui JD, et al. The clinical implications of antitumor immunity in head and neck cancer. Laryngoscope. 2012;122:144–157.
32. Bedi A, Chang X, Noonan K, et al. Inhibition of TGF-beta enhances the in vivo antitumor efficacy of EGF receptor-targeted therapy. Mol Cancer Ther. 2012;11:2429–2439.
33. Sato T, Terai M, Tamura Y, et al. Interleukin 10 in the tumor microenvironment:a target for anticancer immunotherapy. Immunol Res. 2011;51:170–182.
34. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity:a leading role for STAS3. Nat Rev Cancer. 2009;9:798–809.
35. Wang T, Niu G, Kortylewski M, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med. 2004;10:48–54.
36. Kortylewski M, Kujawski M, Wang T, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med. 2005;11:1314–1321.
37. Lee JC, Lee KM, Kim DW, et al. Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol. 2004;172:7335–7340.
38. Dong G, Chen Z, Li ZY, et al. Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma. Cancer Res. 2001;61:5911–5918.
39. Vasquez-Dunddel D, Pan F, Zeng Q, et al. STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J Clin Investig. 2013;123:1580–1589.
40. Califano JA, Khan Z, Noonan KA, et al. Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma. Clin Cancer Res 2015;21:30–38.
41. Young MR, Wright MA, Lozano Y, et al. Increased recurrence and metastasis in patients whose primary head and neck squamous cell carcinomas secreted granulocyte-macrophage colony-stimulating factor and contained CD34+ natural suppressor cells. Int J Cancer. 1997;74:69–74.
42. Nagaraj S, Schrum AG, Cho HI, et al. Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol. 2010;184:3106–3116.
43. Bronte V, Apolloni E, Cabrelle A, et al. Identification of a CD11b+/Gr-1+/cd31+ myeloid orogenitor capable of activating or suppressing CD8+ T cells. Blood. 2000;96:3838–3846.
44. Yu J, Wang Y, Yan F, et al. Noncanonical NF-κB activation mediates STAT3-stimulated IDO upregulation in myeloid-derived suppressor cells in breast cancer. J Immunol. 2014;193:2574–2586.
45. De Palma M, Lewis CE. Macrophage regulation of tumor response to anticancer therapies. Cancer Cell. 2013;23:277–286.
46. Balermpas P, Rodel F, Liberz R, et al. Head and neck cancer relapse after chemoradiotherapy correlates with CD163+ macrophages in primary tumour and CD11b+ myeloid cells in recurrences. Br J Cancer. 2014;111:1509–1518.
47. Fujii N, Shomori K, Shiomi T, et al. Cancer-associated fibroblasts and CD163-positive macrophages in oral squamous cell carcinoma:their clinicopathological and prognostic significance. J Oral Pathol Med. 2012;41:444–451.
48. Noy R, Pollard JW. Tumor-associated macrophages:from mechanisms to therapy. Immunity. 2014;41:49–61.
49. Costa NL, Valadares MC, Souza PP, et al. Tumor-associated macrophages and the profile of inflammatory cytokines in oral squamous cell carcinoma. Oral Oncol. 2013;49:216–223.
50. Siveen KS, Kuttan G. Role of macrophages in tumour progression. Immunol Lett. 2009;123:97–102.
51. Jie HB, Gildener-Leapman N, Li J, et al. Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients. Br J Cancer. 2013;109:2629–2635.
52. Lau KM, Cheng SH, Lo KW, et al. Increase in circulating Foxp3+CD4+CD25high regulatory T cells in nasopharyngeal carcinoma patients. Br J Cancer. 2007;96:617–622.
53. De Costa AM, Schuyler CA, Walker DD, et al. Characterization of the evolution of immune phenotype during the development and progression of squamous cell carcinoma of the head and neck. Cancer Immunol Immunother. 2012;61:927–939.
54. Kerkar SP, Restifo NP. Cellular constituents of immune escape within the tumor microenvironment. Cancer Res. 2012;72:3125–3130.
55. Zou W, Chen L. Inhibitory B7-family molecules in the tumor microenvironment. Nat Rev Immunol. 2008;8:467–477.
56. Woo SR, Turnis ME, Goldberg MV, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012;72:917–927.
57. Johnston RJ, Comps-Agrar L, Hackney J, et al. The immunoreceptor TIGIT regulates antitumor and antivirual CD8(+) T cell effector function. Cancer Cell. 2014;26:923–937.
58. Fourcade J, Sun Z, Benallaoua M, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J EXP Med. 2010;207:2175–2186.
59. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–264.
60. Cho YA, Yoon HJ, Lee JI, et al. Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. Oral Oncol. 2011;47:1148–1153.
61. Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012):an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17(7):956–965.
62. Chow LQ, Haddad R, Gupta S, et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma:results from the phase ib KEYNOTE-012 expansion cohort. J Clin Oncol. 2016;34(32):3838–3845.
63. Ferris RL, Blumenschein G, Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016 Nov 10;375(19):1856–1867.
64. Stransky N, Egloff AM, Tward AD, et al. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011;333:1157–1160.•• This article summarizes the mutational landscape of HPV-negative and HPV-associated HNSCC.
65. Li Q, Prince ME, Moyer JS. Immunotherapy for head and neck squamous cell carcinoma. Oral Oncol. 2015;51(4):299–304.
66. Bloy N, Buque A, Aranda F, et al. Trial watch:naked and vectored DNA-based anticancer vaccines. Onco Immunol. 2015;4:e1026531.
67. Schlom J, Hodge JW, Palena C, et al. Therapeutic cancer vaccines. Adv Cancer Res. 2014;121:67–124.
68. Vergati M, Intrivici C, Huen NY, et al. Strategies for cancer vaccine development. J Biomed Biotechnol. 2010;2010. pii:596432. 2010 Jul 11 [Epub ahead of print].
69. Schuler PJ, Harasymczuk M, Visus C, et al. Phage I dendritic cell p53 peptide vaccine for head and neck cancer. Clin Cancer Res. 2014;20:2433–2444.
70. Voskens CJ, Sewell D, Hertzano R, et al. Induction of mega-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma. Head and Neck. 2012;34(12):1734–1746.
71. Yoshitake Y, Fukuma D, Yuno A, et al. Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS. Clin Cancer Res. 2015;21(2):312–321.
72. Whiteside TL, Letessier E, Hirabayashi H, et al. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck. Cancer Res. 1993;53(23):5654–5662.• This article demonstrates local and systemic activation of TIL by IL-2 in advanced HNSCC patients.
73. De Stefani A, Forni G, Ragona R, et al. Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx. Cancer. 2002;95(1):90–97.
74. Czystowska M, Han J, Szczepanski MJ, et al. IRX-2, a novel immunotherapeutic, protects human T cells from tumor-induced cell death. Cell Death Differ. 2009;16(5):708–718.• This article shows that immunotherapy using IRX-2 protects T cells from tumor-induced apoptosis.
75. Wolf GT, Fee WE, Jr, Dolan RW, et al. Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer. Head Neck. 2011;33(12):1666–1674.
76. Berinstein NL, Wolf GT, Naylor PH, et al. Increased lymphocyte infiltration in patients with head and neck cancer treat with the IRX-2 immunotherapy regimen. Cancer Immunol Immunother. 2012;61:771–782.
77. Rostow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366(10):925–931.
78. Stamell EF, Wolchok JD, Gnjatic S, et al. The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys. 2013;85(2):293–295.
79. Malm IJ, Bruno TC, Fu J, et al. Expression profile and in vitro blockade of programmed death-1 in human papillomavirus-negative head and neck squamous cell carcinoma. Head Neck. 2015;37(8):1088–1095.
80. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012 Jun 28;366(26):2443–2454.